Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
RESEARCH TOOLSreports
Holding ADAP?
Track your performance easily
ADAP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.42 - $2.05
Previous Close$1.21
Volume1.06M
Average Volume (3M)2.23M
Market Cap
$309.40M
Enterprise Value$189.44M
Total Cash (Recent Filing)$143.65M
Total Debt (Recent Filing)$23.69M
Price to Earnings (P/E)―
Beta2.81
Next Earnings
Nov 06, 2024EPS Estimate
-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding1,534,472,670
10 Day Avg. Volume1,780,001
30 Day Avg. Volume2,232,188
Standard Deviation0.48
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)19.49
Price to Sales (P/S)13.13
Price to Cash Flow (P/CF)9.80
P/FCF Ratio10.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.32
Enterprise Value/Gross Profit3.14
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
$2.36Price Target Upside95.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Adaptimmune Therapeutics News
PremiumCompany Announcements
Adaptimmune’s TECELRA®: FDA Approval Marks Solid Tumor Breakthrough
Bulls Say, Bears Say
Bulls Say
Commercial ReadinessManagement continues to express confidence in commercial readiness for Tecelra following the recent FDA accelerated approval.
FDA ApprovalADAP recently received FDA accelerated approval for Tecelra, marking the first approval of a cell therapy to treat solid tumors.
Market ExpansionManagement reiterated its plan to launch afami-cel at 6-10 select ATCs in 2024, growing to approximately 30 ATCs within 24 months.
Bears Say
Commercial ExecutionThe equally hard part now comes: commercial execution on the launch, and driving revenue, where the opportunity is somewhat limited.
Investor SentimentADAP shares are now trading down 10% intra-day, reflecting negative investor sentiment related to the headline news.
Strategic CollaborationThe strategic collaboration with Genentech to develop an allogeneic cell therapy program has been terminated.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ADAP FAQ
What was Adaptimmune Therapeutics’s price range in the past 12 months?
Adaptimmune Therapeutics lowest stock price was $0.42 and its highest was $2.05 in the past 12 months.
What is Adaptimmune Therapeutics’s market cap?
Currently, no data Available
When is Adaptimmune Therapeutics’s upcoming earnings report date?
Adaptimmune Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 73 days.
How were Adaptimmune Therapeutics’s earnings last quarter?
Adaptimmune Therapeutics released its earnings results on Aug 12, 2024. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.044 by $0.084.
Is Adaptimmune Therapeutics overvalued?
According to Wall Street analysts Adaptimmune Therapeutics’s price is currently Undervalued.
Does Adaptimmune Therapeutics pay dividends?
Adaptimmune Therapeutics does not currently pay dividends.
What is Adaptimmune Therapeutics’s EPS estimate?
Adaptimmune Therapeutics’s EPS estimate is -$0.01.
How many shares outstanding does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has 255,745,440 shares outstanding.
What happened to Adaptimmune Therapeutics’s price movement after its last earnings report?
Adaptimmune Therapeutics reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.044. Following the earnings report the stock price went up 10.101%.
Which hedge fund is a major shareholder of Adaptimmune Therapeutics?
Among the largest hedge funds holding Adaptimmune Therapeutics’s share is Matrix Capital Management Company, LP. It holds Adaptimmune Therapeutics’s shares valued at 38M.
---
Adaptimmune Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.36 (95.04% Upside)
$2.36 (95.04% Upside)
Blogger Sentiment
Bullish
ADAP Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 8.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.28%
12-Months-Change
Fundamentals
Return on Equity
-65.09%
Trailing 12-Months
Asset Growth
-6.20%
Trailing 12-Months
Company Description
Adaptimmune Therapeutics
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
---
ADAP Earnings Call
Q2 2024
0:00 / 0:00
---
ADAP Stock 12 Month Forecast
Average Price Target
$2.36
▲(95.04% Upside)
Technical Analysis
Best Analysts Covering ADAP
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
+55.55%
reiterated a buy rating 13 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +55.55% per trade.
---